ライフサイエンスコーパス: polyarthritis

1 thritidis is a rat pathogen causing a severe polyarthritis.

2 animal model of T cell-mediated inflammatory polyarthritis.

3 s ranging from severe meningoencephalitis to polyarthritis.

4 a natural pathogen of rats, causing an acute polyarthritis.

5 ancer survival in patients with inflammatory polyarthritis.

6 stent disease or disease that evolved into a polyarthritis.

7 patients following the onset of inflammatory polyarthritis.

8 in the cohort of patients with inflammatory polyarthritis.

9 compared with patients without inflammatory polyarthritis.

10 are-based register of new-onset inflammatory polyarthritis.

11 ) were at an increased risk for inflammatory polyarthritis.

12 5 years after presentation with inflammatory polyarthritis.

13 reatment, both control dogs developed severe polyarthritis.

14 o present with undifferentiated inflammatory polyarthritis.

15 a variety of autoimmune disorders, including polyarthritis.

16 monitored the impact on SCW-induced erosive polyarthritis.

17 tly reduced the severity of adjuvant-induced polyarthritis.

18 r manifestations in a patient with carcinoma polyarthritis.

19 rder which can be associated with a JRA-like polyarthritis.

20 elationship of their immunodeficiency to the polyarthritis.

21 s may have predisposed to the development of polyarthritis.

22 the rat hindpaw as well as adjuvant-induced polyarthritis (21 d).

23 m tuberculosis H37Ra leads to development of polyarthritis (adjuvant-induced arthritis; AA) that shar

24 Two of the patients with polyarthritis also had IgA deficiency.

25 om fetal human cartilage induces progressive polyarthritis, an experimental disease similar to human

26 B10.DQ8 transgenic mice develop polyarthritis and Ab's to CII only.

27 experimental polychondritis, exhibiting both polyarthritis and auricular chondritis.

28 ype, mortality in patients with inflammatory polyarthritis and cancer was significantly increased (ha

29 to create a new model of chronic autoimmune polyarthritis and characterize the associated CII-specif

30 this is the first animal model showing both polyarthritis and heart disease as a direct result of TN

31 n a model of Streptococcal cell wall-induced polyarthritis and liver inflammation in rats.

32 OR 1.8, 95% CI 1.4-2.4) between inflammatory polyarthritis and the presence of any shared epitope (SE

33 henotypically characterized by granulomatous polyarthritis and uveitis.

34 ll lung carcinoma, the signs and symptoms of polyarthritis and vasculitis had disappeared completely.

35 tis, 45 with rheumatoid factor [RF]-negative polyarthritis, and 21 with systemic disease) were isolat

36 ERA, persistent oligoarthritis, RF-negative polyarthritis, and systemic JIA patients, respectively.

37 with persistent oligoarthritis, RF-negative polyarthritis, and systemic JIA subtypes, up-regulation

38 y care-based inception study of inflammatory polyarthritis, and were matched for age and sex to 2 con

39 ch as systemic lupus erythematosus (SLE) and polyarthritis are characterized by chronic cytokine over

40 s that cause weeks to months of debilitating polyarthritis/arthralgia, which is often poorly managed

41 Often, the polyarthritis at presentation of SLE cannot be distingui

42 ing 1996, the clinical spectrum of the acute polyarthritis caused by parvovirus B19 was further delin

43 al was reduced in patients with inflammatory polyarthritis compared with patients without inflammator

44 y was rescued by loss of STING function, and polyarthritis completely prevented because cytosolic DNA

45 Finally, a severe polyarthritis developed in a majority of HLA-DQ8+,H-2Ab0

46 placebo-controlled trial, SLE patients with polyarthritis, discoid lesions, or pleuritis and/or peri

47 with persistent or extended oligoarthritis, polyarthritis (either rheumatoid factor [RF] positive or

48 (SCW)-induced model of inflammatory erosive polyarthritis, endogenous SLPI was unexpectedly upregula

49 ligoarthritis and rheumatoid factor-negative polyarthritis, erythrocyte sedimentation rate (ESR), C-r

50 causes a chronic debilitating polyarthralgia/polyarthritis, for which current treatments are often in

51 We recruited 532 patients with inflammatory polyarthritis from the Norfolk Arthritis Register and ty

52 ; treatment differences were greatest in the polyarthritis group.

53 All 3 patients with polyarthritis had evidence of impaired T cell function.

54 All 3 patients with polyarthritis had evidence of more extensive immunoregul

55 -dose oral methotrexate (MTX) for persistent polyarthritis has been shown to be effective by the USA/

56 ause mortality in patients with inflammatory polyarthritis (hazard ratio, 1.16 [95% CI, 1.03-1.31], P

57 e adjuvant, resulting in a chronic relapsing polyarthritis in >80% of the mice 4 weeks after immuniza

58 s the development of seronegative, symmetric polyarthritis in a patient with relapsing-remitting MS,

59 We report a case of polyarthritis in a young man with PRP in which magnetic

60 new spontaneous mutation that causes severe polyarthritis in bone phenotype spontaneous mutation 1 (

61 avirus that causes epidemics of debilitating polyarthritis in humans.

62 The spontaneous development of destructive polyarthritis in mice transgenic for an autoreactive T-c

63 The prevalence of polyarthritis in patients with chromosome 22q11.2 deleti

64 Mycoplasma arthritidis causes acute polyarthritis in rats and chronic proliferative arthriti

65 Adjuvant-induced polyarthritis in rats was used as a model of chronic inf

66 We describe 2 patients presenting with polyarthritis in whom the synovial fluid (1 patient) or

67 elected patients with new-onset inflammatory polyarthritis (IP) has not been examined.

68 f RA in subjects with new-onset inflammatory polyarthritis (IP) over the first 5 years of observation

69 utcome and OC use in women with inflammatory polyarthritis (IP).

70 sability in patients with early inflammatory polyarthritis (IP).

71 patients newly presenting with inflammatory polyarthritis (IP).

72 n together, proteoglycan-induced progressive polyarthritis is dictated by three major components: gen

73 ture regarding IFNalpha- and IFNbeta-induced polyarthritis is reviewed, and possible mechanisms for I

74 When present with inflammatory symmetric polyarthritis, it is pathognomonic of rheumatoid arthrit

75 ne K/BxN arthritis model, a distal symmetric polyarthritis mediated by IgG immune complexes.

76 t patients, ages 18-70, with an inflammatory polyarthritis of <12 months' duration who were recruited

77 f 680 consecutive patients with inflammatory polyarthritis, of whom 404 satisfied the American Colleg

78 iated with an increased risk of inflammatory polyarthritis or rheumatoid arthritis.

79 ountered pathology in three rodent models of polyarthritis: rat and mouse collagen-induced arthritis,

80 f all patients who had onset of inflammatory polyarthritis (swelling of > or =2 joints) during 1990.

81 joint involvement, small joint involvement, polyarthritis, symmetric arthritis, spinal pain, fever,

82 ibes a patient who presented with an unusual polyarthritis syndrome.

83 eumatoid factor (RF)-positive or RF-negative polyarthritis, systemic JIA, or extended oligoarthritis

84 Furthermore, the progressive polyarthritis that is characteristic in susceptible C3H/

85 twice daily) was a symptomatic inflammatory polyarthritis that persisted for up to 8 weeks after dis

86 yel-KO) mice) triggers a spontaneous erosive polyarthritis that resembles rheumatoid arthritis in pat

87 hritis (RA) causes a symmetric, inflammatory polyarthritis that results in joint destruction and sign

88 long-term inflammatory pain models (CFA and polyarthritis) the same pattern of SP release and SPR ac

89 ith chromosome 22q11.2 deletion syndrome and polyarthritis underwent laboratory evaluations of immuno

90 ures on outcome in patients with unexplained polyarthritis (UPA) (from the early undifferentiated CTD

91 terations in nociceptive pathways induced by polyarthritis using the collagen antibody-induced arthri

92 The risk for development of inflammatory polyarthritis was compared between subjects in the highe

93 Chronic autoimmune polyarthritis was induced and was dependent on the antig

94 Polyarthritis was induced in rats by injection of Freund

95 ng this cohort of patients with inflammatory polyarthritis was not increased compared with that in th

96 cts who sought primary care for inflammatory polyarthritis were analyzed.

97 and 2002, 88 new patients with inflammatory polyarthritis were identified and matched with 176 contr

98 Patients with new cases of inflammatory polyarthritis were identified by linkage with the Norfol

99 iting toxicity (DLT) was severe inflammatory polyarthritis, which seemed to be a cumulative toxicity.

100 neally with pristane oil to induce a chronic polyarthritis, which was monitored by visual scoring.

101 eumatoid arthritis is a chronic inflammatory polyarthritis whose etiology remains uncertain.

102 allows differentiation of presentation of a polyarthritis with a good prognosis (spondyloarthropathy

103 l lesions, whereas all control dogs had mild polyarthritis with periarteritis.

104 IA) represents an animal model of autoimmune polyarthritis with significant similarities to human rhe

105 IA) represents an animal model of autoimmune polyarthritis with similarities to human rheumatoid arth

106 al polychondritis, auricular chondritis, and polyarthritis, with clinical and histological similariti